Tags

Type your tag names separated by a space and hit enter

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
J Nephrol. 2022 06; 35(5):1467-1478.JN

Abstract

BACKGROUND

After the reports of severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose of ChAdOx1-S-nCoV-19 vaccine were recommended a second dose of Pfizer's BNT162b2 vaccine. In hemodialysis patients, we compared the humoral immunogenicity and tolerability of homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) and BNT162b2/BNT162b2 (BNT/BNT) with heterologous vaccination of first dose of ChAdOx1-nCoV-19 and a second dose with BNT162b2 (ChAd/BNT).

METHODS

In a multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels, Nucleocapsid-protein-IgG-antibodies, and vaccine tolerability were assessed 6 weeks after second SARS-CoV-2 vaccination in 137 hemodialysis patients and 24 immunocompetent medical personnel.

RESULTS

In COVID-19-naïve hemodialysis patients, significantly higher median SARS-CoV-2-spike IgG levels were found after ChAd/BNT (N = 16) compared to BNT/BNT (N = 100) or ChAd/ChAd (N = 10) (1744 [25th-75th percentile 276-2840] BAU/mL versus 361 [25th-75th percentile 120-936] BAU/mL; p = 0.009; 1744 [25th-75th percentile 276-2840] BAU/mL versus 100 [25th-75th percentile 41-346] BAU/mL; p = 0.017, respectively). Vaccinated, COVID-19-naïve medical personnel had median SARS-CoV-2 spike-IgG levels of 650 (25th-75th percentile 217-1402) BAU/mL and vaccinated hemodialysis patients with prior COVID-19 7047 (25th-75th percentile 685-10,794) BAU/mL (N = 11). In multivariable regression analysis, heterologous vaccination (ChAd/BNT) of COVID-19-naïve hemodialysis patients was independently associated with SARS-CoV-2 spike-IgG levels. The first dose of ChAd and the second dose of BNT after the first vaccination with ChAd (heterologous vaccination, ChAd/BNT) were associated with more frequent but manageable side effects compared with homologous BNT.

CONCLUSIONS

Within the limitations of this study, heterologous vaccination with ChAd/BNT appears to induce stronger humoral immunity and more frequent but manageable side effects than homologous vaccination with BNT/BNT or with ChAd/ChAd in COVID-19-naïve hemodialysis patients.

Links

PMC Free PDF

Authors+Show Affiliations

Haase M
Diaverum Renal Care Center, Potsdam, Germany. michael.haase@med.ovgu.de. Diaverum AB, Hyllie Boulevard 39, 215 37, Malmö, Sweden. michael.haase@med.ovgu.de. Medical Faculty, Otto-Von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. michael.haase@med.ovgu.de.
Lesny P
Diaverum Renal Care Center, Potsdam, Germany.
Anderson M
Abbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Cloherty G
Abbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Stec M
Abbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Haase-Fielitz A
Brandenburg Medical School Theodor Fontane, 16816, Neuruppin, Germany. Faculty of Health Sciences Brandenburg, 14469, Potsdam, Germany. Institute of Integrated Health Care Systems Research & Social Medicine, Otto-Von-Guericke-University Magdeburg, 39120, Magdeburg, Germany. Department of Cardiology, Brandenburg Heart Center, Immanuel Hospital, 16321, Bernau, Germany.
Haarhaus M
Diaverum AB, Hyllie Boulevard 39, 215 37, Malmö, Sweden. Division of Renal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Santos-Araújo C
Institute of Integrated Health Care Systems Research & Social Medicine, Otto-Von-Guericke-University Magdeburg, 39120, Magdeburg, Germany. Division of Renal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Veiga PM
School of Education, Polytechnic Institute of Viseu, Viseu, Portugal. NECE Research Unit in Business Sciences, University of Beira Interior, Covilhã, Portugal.
Macario F
Diaverum AB, Hyllie Boulevard 39, 215 37, Malmö, Sweden.

MeSH

Antibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunoglobulin GProspective StudiesRenal DialysisSARS-CoV-2VaccinationViral Vaccines

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

35084719

Citation

Haase, Michael, et al. "Humoral Immunogenicity and Tolerability of Heterologous ChAd/BNT Compared With Homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 Vaccination in Hemodialysis Patients : a Multicenter Prospective Observational Study." Journal of Nephrology, vol. 35, no. 5, 2022, pp. 1467-1478.
Haase M, Lesny P, Anderson M, et al. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. J Nephrol. 2022;35(5):1467-1478.
Haase, M., Lesny, P., Anderson, M., Cloherty, G., Stec, M., Haase-Fielitz, A., Haarhaus, M., Santos-Araújo, C., Veiga, P. M., & Macario, F. (2022). Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. Journal of Nephrology, 35(5), 1467-1478. https://doi.org/10.1007/s40620-022-01247-7
Haase M, et al. Humoral Immunogenicity and Tolerability of Heterologous ChAd/BNT Compared With Homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 Vaccination in Hemodialysis Patients : a Multicenter Prospective Observational Study. J Nephrol. 2022;35(5):1467-1478. PubMed PMID: 35084719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. AU - Haase,Michael, AU - Lesny,Paul, AU - Anderson,Mark, AU - Cloherty,Gavin, AU - Stec,Michael, AU - Haase-Fielitz,Anja, AU - Haarhaus,Mathias, AU - Santos-Araújo,Carla, AU - Veiga,Pedro Mota, AU - Macario,Fernando, Y1 - 2022/01/27/ PY - 2021/11/23/received PY - 2022/01/01/accepted PY - 2022/1/28/pubmed PY - 2022/6/25/medline PY - 2022/1/27/entrez KW - COVID-19 KW - Kidney KW - SARS-CoV-2 spike IgG KW - Side effects KW - mRNA-/vectored vaccines SP - 1467 EP - 1478 JF - Journal of nephrology JO - J Nephrol VL - 35 IS - 5 N2 - BACKGROUND: After the reports of severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose of ChAdOx1-S-nCoV-19 vaccine were recommended a second dose of Pfizer's BNT162b2 vaccine. In hemodialysis patients, we compared the humoral immunogenicity and tolerability of homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) and BNT162b2/BNT162b2 (BNT/BNT) with heterologous vaccination of first dose of ChAdOx1-nCoV-19 and a second dose with BNT162b2 (ChAd/BNT). METHODS: In a multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels, Nucleocapsid-protein-IgG-antibodies, and vaccine tolerability were assessed 6 weeks after second SARS-CoV-2 vaccination in 137 hemodialysis patients and 24 immunocompetent medical personnel. RESULTS: In COVID-19-naïve hemodialysis patients, significantly higher median SARS-CoV-2-spike IgG levels were found after ChAd/BNT (N = 16) compared to BNT/BNT (N = 100) or ChAd/ChAd (N = 10) (1744 [25th-75th percentile 276-2840] BAU/mL versus 361 [25th-75th percentile 120-936] BAU/mL; p = 0.009; 1744 [25th-75th percentile 276-2840] BAU/mL versus 100 [25th-75th percentile 41-346] BAU/mL; p = 0.017, respectively). Vaccinated, COVID-19-naïve medical personnel had median SARS-CoV-2 spike-IgG levels of 650 (25th-75th percentile 217-1402) BAU/mL and vaccinated hemodialysis patients with prior COVID-19 7047 (25th-75th percentile 685-10,794) BAU/mL (N = 11). In multivariable regression analysis, heterologous vaccination (ChAd/BNT) of COVID-19-naïve hemodialysis patients was independently associated with SARS-CoV-2 spike-IgG levels. The first dose of ChAd and the second dose of BNT after the first vaccination with ChAd (heterologous vaccination, ChAd/BNT) were associated with more frequent but manageable side effects compared with homologous BNT. CONCLUSIONS: Within the limitations of this study, heterologous vaccination with ChAd/BNT appears to induce stronger humoral immunity and more frequent but manageable side effects than homologous vaccination with BNT/BNT or with ChAd/ChAd in COVID-19-naïve hemodialysis patients. SN - 1724-6059 UR - https://www.unboundmedicine.com/medline/citation/35084719/Humoral_immunogenicity_and_tolerability_of_heterologous_ChAd/BNT_compared_with_homologous_BNT/BNT_and_ChAd/ChAd_SARS_CoV_2_vaccination_in_hemodialysis_patients_:_A_multicenter_prospective_observational_study_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓6 ↑32]

Related Citations

More